Table S2: Characteristics of treatment-experienced patients receiving a second or subsequent ART regimen (n=2866)

Variables	NNRTI (n=716)	PI (n=1575)	INSTI (n=575)
Age at inclusion (in years)			
Mean (SD)	43.5 (9.8)	43.0 (9.7)	44.3 (11.5)
Sex (%)			
Male	613 (85.6%)	1264 (80.2%)	495 (86.1%)
Risk factor for HIV acquisition			
MSM (%)	449 (62.7%)	949 (60.2%)	399 (69.4%)
Bisexual (%)	18 (2.5%)	51 (3.2%)	11 (1.9%)
Heterosexual (%)	154 (21.5%)	380 (24.1%)	82 (14.3%)
From endemic countries (%)	113 (15.8%)	241 (15.3%)	56 (9.7%)
Vertical transmission (%)	9 (1.3%)	10 (0.6%)	4 (0.7%)
Delay in ART treatment initiation (in years)			
Mean (SD)	1.7 (3.4)	1.8 (3.6)	1.7 (3.9)
ART duration before inclusion (in years)			
Mean (SD)	5.8 (4.7)	6.3 (5.3)	5.8 (5.9)
Time since diagnosis at inclusion (in years)			
Mean (SD)	7.2 (6.0)	7.9 (6.3)	7.2 (7.1)
Treatment changes before inclusion			
Yes	332 (46.4%)	873 (55.4%)	174 (30.3%)
Viral load (copies/ml) at inclusion			
<50	277 (38.7%)	475 (30.2%)	181 (31.5%)
50-10000	209 (29.2%)	496 (31.5%)	168 (29.2%)
>10000	175 (24.4%)	520 (33.0%)	204 (35.5%)
MD	55 (7.7%)	84 (5.3%)	22 (3.8%)
Median (25%-75%)	270.0 (49.5-12082.0)	462.0 (49.5-38000.0)	601.0 (49.5-38400.0)
CD4 count at inclusion (cells/mm3)			
<200	89 (12.4%)	362 (23.0%)	70 (12.2%)
200-350	207 (28.9%)	440 (27.9%)	149 (25.9%)
>350	362 (50.6%)	684 (43.4%)	327 (56.9%)
MD	58 (8.1%)	89 (5.7%)	29 (5.0%)
Median (25%-75%)	381.5 (260.0-580.0)	330.0 (207.0-500.0)	410.0 (279.0-597.0)
CD8 count at inclusion (cells/mm3)			
<800	259 (36.2%)	615 (39.0%)	202 (35.1%)
≥800	312 (43.6%)	727 (46.2%)	235 (40.9%)
MD	145 (20.2%)	233 (14.8%)	138 (24.0%)
Median (25%-75%)	850.0 (600.0-1150.0)	850.0 (582.0-1210.0)	841.0 (610.0-1180.0)
Ratio CD4/CD8 at inclusion			
<1	498 (69.6%)	1259 (79.9%)	387 (67.3%)
>1	73 (10.2%)	82 (5.2%)	49 (8.5%)
MD	145 (20.2%)	234 (14.9%)	139 (24.2%)
Median (25%-75%)	0.4 (0.2-0.6)	0.4 (0.3-0.7)	0.5 (0.3-0.7)
CD4 nadir before inclusion			
<200	124 (17.3%)	457 (29.0%)	99 (17.2%)
200-350	235 (32.8%)	490 (31.1%)	168 (29.2%)
>350	299 (41.8%)	539 (34.2%)	279 (48.5%)
MD	58 (8.1%)	89 (5.7%)	29 (5.1%)
Median (25%-75%)	337.5 (230.0-510.0)	281.0 (180.0-427.0)	360.0 (240.0-500.0)
Hepatitis B before inclusion			
Positive for HBsAg	45 (6.3%)	80 (5.1%)	16 (2.8%)
Negative for HBsAg	541 (75.6%)	1189 (75.5%)	464 (80.7%)
Not documented	130 (18.1%)	306 (19.4%)	95 (16.5%)
Hepatitis C before inclusion			
Positive for anti-HCV	46 (6.4%)	190 (12.1%)	29 (5.0%)
Negative for anti-HCV	374 (52.2%)	753 (47.8%)	343 (59.7%)

Not documented	296 (41.4%)	632 (40.1%)	203 (35.3%)
Cytomegalovirus serostatus			
Positive	172 (24.0%)	387 (24.6%)	110 (19.1%)
Negative	32 (4.5%)	82 (5.2%)	49 (8.5%)
Not documented	512 (71.5%)	1106 (70.2%)	416 (72.4%)
Previous exposure to mono/dual NRTI therapy before inclusion			
Yes	53 (7.4%)	291 (18.5%)	57 (9.9%)
Previously documented virologic failure before inclusion			
Yes	21 (2.9%)	166 (10.5%)	21 (3.7%)
Year of inclusion			
2006-2009	517 (72.2%)	1268 (80.5%)	161 (28.0%)
2010-2013	176 (24.6%)	286 (18.2%)	226 (39.3%)
2014-2017	23 (3.2%)	21 (1.3%)	188 (32.7%)

Abbreviations: NNRTI, non-nucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor; INSTI, Integrase Strand Transfer Inhibitor; ART: Antiretroviral therapy; SD, standard deviation; HIV, human immunodeficiency virus; MSM, men who have sex with men; MD, missing data; HBsAg, hepatitis B surface antigen; HVC, hepatitis C virus;